The Patent Finder

Terms ending in 2033

Interpace Diagnostics Corporation

Every in-force patent on Interpace Diagnostics Corporation's record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 10,255,410Methods for Treating Barrett's Metaplasia and Esophageal Adenocarcinoma
In force
 · High confidence
Interpace Diagnostics CorporationIn forceHigh confidence
US 12,205,676Methods for Treating Barrett's Metaplasia and Esophageal Adenocarcinoma
In force
 · High confidence
Interpace Diagnostics CorporationIn forceHigh confidence
US 10,131,942Methods for Treating Barrett's Metaplasia and Esophageal Adenocarcinoma
In force
 · High confidence
Interpace Diagnostics CorporationIn forceHigh confidence
US 10,444,239Methods for Measuring Carcinoembryonic Antigen
In force
 · Medium confidence
Interpace Diagnostics CorporationIn forceMedium confidence
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited